eLife Assessment: "This valuable study identifies and characterizes probe binding errors in a widely used commercial [ST] platform...The authors provide convincing evidence...[T]his work provides an essential quality control resource that will improve data interpretation"

I would also like to note that, given the results presented in our paper, previous results presented in the publication describing the Xenium technology and demonstrated using this gene panel (Janesick et al, Nature Communication, December 2023) are in part erroneous. However...

...we chose not to submit this as a Matters Arising since that process requires confidentiality and can be rather lengthy. Given the urgency imposed by the cost and wide usage of these ST technologies, we felt it was more responsible to share this work as quickly as possible.

Further, we believe this paper will benefit from eLife's continuous post-publication public peer review. We hope this will enable the rapid dissemination of these insights + allow for constructive criticisms from industry + academic experts to be openly considered by all readers.